Glucose phosphorylation and glucose transport are tightly coupled phenomena. Isoenzymes of HK (HK-I to HK-IV) catalyze the first committed intracellular step of glucose metabolism, the conversion of glucose to G-6-P. HK-I, HK-II, HK-III are single-chain peptides that have a number of properties in common, including a very high affinity for glucose and product inhibition by G-6-P.

Twenty-one years ago, when Steve and I were still trying to spell the word “diabetes” correctly, there was a young endocrinologist in Atlanta who was setting the diabetes world on its ear by using insulin pumps on patients before it was the last resort. I will never forget the presentation …

Study authors sought to characterize the tolerance test, and HbA1c—in a population of patients with coronary artery disease (CAD).

Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.

Study aims to distinguish different antidiabetic drugs and their effect on osteoporosis in people with diabetes.

People with type 1 diabetes receiving once-daily injection of glucagon-blocking drug, REMD-477 can reduce their insulin use considerably and improve blood glucose levels without altering hypoglycemia.

Older adults taking five or more drugs are likely to exhibit negative side effects.

Dr. Bruce Bode, MD, FACE, shares his knowledge on the artificial pancreas and diabetes pumps. Dr. Bode is a professor of medicine at Emory University School of Medicine in Atlanta, GA. He has a strong affinity for working with children and young adults with diabetes and is considered one of the leading experts in the world on insulin delivery and glucose sensing.

Dr. Bruce Bode discusses the artificial pancreas, advances in continuous glucose monitoring, and insulin pumps.

Dr. Bruce Bode talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about the trial and use of the artificial pancreas.